Previous 10 | Next 10 |
Results published in Journal of Vascular Surgery – Vascular Science DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, a...
2023-07-28 17:39:07 ET Gainers: Annexon ( ANNX ) +5% . Fluence Energy ( FLNC ) +4% . Humacyte ( HUMA ) +3% . Stoke Therapeutics ( STOK ) +3% . Brightcove ( BCOV ) +3% . Losers: Silk Road Medical ( SILK ) -5% . ...
-Top-line results planned to be released in third quarter 2023- -Trial results are intended to support Biologics License Application (BLA) planned for fourth quarter 2023- DURHAM, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology...
2023-06-07 10:01:47 ET Gainers: Avrobio ( AVRO ) +10% . Cardiff Oncology ( CRDF ) +8% . IceCure Medical ( ICCM ) +7% . Humacyte ( HUMA ) +6% . TScan Therapeutics ( TCRX ) +4% . Losers: Vaxart ( VXRT ) -27% . Carism...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founde...
2023-05-12 18:40:22 ET Summary Today, we put Humacyte, Inc. back into the spotlight for the first time since last October. This intriguing developmental concern closed on an important financing deal this week and got a nice shout out from an analyst firm. An investment analysi...
2023-05-12 11:27:02 ET Humacyte Inc. (HUMA) Q1 2023 Results Conference Call May 12, 2023 08:00 AM ET Company Participants Lauren Marek - LifeSci Advisors Laura Niklason - Founder, President, CEO and Director Dale Sander - CFO, Chief Corporate Development Officer ...
2023-05-12 07:07:31 ET Humacyte press release ( NASDAQ: HUMA ): Q1 GAAP EPS of -$0.36 misses by $0.15 . The Company reported cash, cash equivalents and short-term investments of $131.7 million as of March 31, 2023. Humacyte believes that its cash, cash equival...
- Human Acellular Vessel™ (HAV™) granted second RMAT designation by the FDA, for Vascular Trauma - - Completion of enrollment in Phase 3 trial of HAV in Hemodialysis Access in End-Stage Renal Disease Patients - - Conference call and live webcast at 8:00 a.m. ET tod...
- $40 million upfront, $20 million upon FDA acceptance of HAV BLA in vascular trauma, $40 million upon FDA approval of HAV in vascular trauma, $50 million upon achievement of certain sales milestones, and $10 million equity option - - Proceeds to support planned development and commerci...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 16, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, announced the addition of pharmaceutical industry veteran Dr. John P. Bamforth and di...
Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercia...
2024-07-01 10:28:20 ET Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it ma...